Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections
Most Products Remain In Preclinical Development
Executive Summary
Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a look at Alzheimer’s drug development; US-China decoupling irks Chinese biotech firms; seven potential blockbuster approvals in 2023; Novo Nordisk’s cardiovascular strategy; and a look at the vaccine and drug pipeline for monkeypox.
Monkeypox Is A Different Drug Development Ballgame From COVID-19
SIGA chief scientific officer Dennis Hruby spoke with Scrip about how the company is developing its drug, Tpoxx, to address the monkeypox outbreak.
Cellarity Takes Broader, Whole-Cell Approach To Drug Discovery
CEO Fabrice Chouraqui spoke with Scrip about the company’s new $121m financing and its use of machine learning to target the whole cell instead of molecular targets in novel therapies.